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Abstract
Background: Glioblastomas are invasive therapy resistant brain tumors with extremely poor prognosis. The Glioma
initiating cell (GIC) population contributes to therapeutic resistance and tumor recurrence. Targeting GIC-associated
gene candidates could significantly impact GBM tumorigenicity. Here, we investigate a protein kinase, PBK/TOPK as
a candidate for regulating growth, survival and in vivo tumorigenicity of GICs.
Methods: PBK is highly upregulated in GICs and GBM tissues as shown by RNA and protein analyses. We knocked
down PBK using shRNA vectors and inhibited the function of PBK protein with a pharmacological PBK inhibitor,
HITOPK-032. We assessed viability, tumorsphere formation and apoptosis in three patient derived GIC cultures.
Results: Gene knockdown of PBK led to decreased viability and sphere formation and in one culture an increase in
apoptosis. Treatment of cells with inhibitor HITOPK-032 (5 μM and 10 μM) almost completely abolished growth and
elicited a large increase in apoptosis in all three cultures. HI-TOPK-032 treatment (5 mg/kg and 10 mg/kg bodyweight)
in vivo resulted in diminished growth of experimentally induced subcutaneous GBM tumors in mice. We also carried
out multi-culture assays of cell survival to investigate the relative effects on GICs compared with the normal neural
stem cells (NSCs) and their differentiated counterparts. Normal NSCs seemed to withstand treatment slightly better
than the GICs.
Conclusion: Our study of identification and functional validation of PBK suggests that this candidate can be a
promising molecular target for GBM treatment.
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Background
Glioblastoma multiforme (GBM) is both the most com-
mon and the most malignant primary brain tumor.
Despite aggressive treatment with surgical resection,
chemotherapy and radiotherapy, median survival is
only one year [1, 2].
Several studies suggest that GBM is hierarchically orga-
nized. The apex of this hierarchy consists of a subgroup
of cells functionally defined by the ability to self-renew
and to reproduce the tumor of origin in orthotopic trans-
plantation models [3–5]. Although it remains unclear
whether a cancer cell with stem-like properties initiates
GBM, this subgroup of GBM cells shares a number of
properties with neural stem/ progenitor cells from the
normal adult human brain, and are most commonly
referred to as glioma initiating cells (GICs). GICs are
relatively unaffected by irradiation and chemotherapy
and are thought to be important in therapeutic resistance
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and tumor recurrence [6–8]. Identification of therapeutic
targets in GICs thus offers promise for the development
of novel treatments for GBM [9–11].
To this end, we have performed comparative gene ex-
pression profiling in GICs and in stem cells from the nor-
mal adult human brain and identified a number of genes
and pathways that are differentially regulated in GICs
[12] (Stangeland et al., submitted). The PDZ-binding
kinase/T-LAK cell-originated protein kinase (PBK/
TOPK) was highly up-regulated in GICs from all patients
we studied, also confirmed at the protein level (Stangeland
et al., submitted). Protein kinases play key roles in the
regulation of intracellular pathways that control cell
growth and survival [13] and are often involved in the
precipitation of malignancy. Inhibition of protein kinases
is therefore considered a potentially fruitful approach for
arresting the growth of tumors [14–16]. Previously, PBK/
TOPK, a serine-threonine kinase and a member of
MAPKK family, has been shown to play important roles
in both normal and cancer cells [17–22]. Among normal
cell types, PBK/TOPK is expressed in highly proliferating
cells such as spermatocytes, in several fetal tissues as well
as in neural stem and progenitor cells [18, 23]. Studies of
neural progenitor cells show that phospho-PBK/TOPK is
detected specifically in M-phase in association with con-
densed chromatin [18]. PBK/TOPK acts as a MAP kinase
kinase by phosphorylation of P38 mitogen-activated pro-
tein kinase (MAPK) [17, 24] and is active during the
mitotic phase of the cell cycle [17]. During mitosis, PBK/
TOPK and cdk1/cyclin B1 complex promote cytokinesis
through phosphorylation of a protein regulator of cytokin-
esis 1 (PRC1) [25–27] and a positive feedback loop
between PBK/TOPK and ERK2 promotes uncontrolled
proliferation [21]. There are also studies suggesting a role
for PBK/TOPK in the sensing and repair of DNA damage
through phosphorylation of histone H2AX [17, 22, 27].
Together these studies suggest that PBK/TOPK may play
an important role in linking extracellular signals to signal-
ing pathways that influence cell proliferation.
The goal of the present study was to investigate the
functional significance of PBK/TOPK up-regulation in
GBM. We show that knockdown of PBK/TOPK expres-
sion using lentiviral short hairpin RNA (shRNA) vectors,
as well as inhibition by a specific antagonist HI-TOPK-
032 [28], reduces cell viability and sphere formation in
vitro. HI-TOPK-032 treatment also leads to a massive
increase in apoptotic cells. Further, treatment with HI-
TOPK-032 in vivo results in a significant dose-dependent
decrease of tumor growth. We also investigated the rela-
tive effects on tumor cells compared with normal brain
stem cells and their differentiated counterparts. Normal
NSCs seemed to withstand treatment slightly better than
GICs and both normal- and tumor-derived differentiated
cells fared better than GICs. PBK should therefore be
investigated further as a putative target for molecular
therapy in GBM.
Results
PBK is upregulated in seven different patient-derived GIC
cultures
To assess PBK expression in GBM, we first investigated
the mRNA and protein levels of PBK in GIC cultures
derived from human brain tumor and in normal sam-
ples. We first compared mRNA levels in seven GIC
cultures and in the neural fetal progenitor cell line (NFCs,
official name: ReNcell, Millipore) to those in two NSC
cultures, using qPCR. qPCR analysis showed that PBK
mRNA expression in GIC cultures is much higher than in
NSCs (Fig. 1a, Additional file 1: Table S1). We have also
assessed the expression of PBK in GBM tissue samples
from TCGA. This analysis showed that PBK was signifi-
cantly up-regulated in the proneural and down-regulated
in the mesenchymal subtypes of GBM (Fig. 1b).
Immunostaining of cryosections of GBM tumorspheres
(T65 and T08) confirmed high protein expression and
demonstrated an extensive cytoplasmic location of PBK in
tumorspheres derived from these GIC cultures (Fig. 1c-h).
Immunostaining in the respective primary GBM tissues
revealed a higher level of PBK than in surrounding normal
cortical tissue, indicating that the high level of expression
is not a culturing artifact (Fig. 1i, j). Western blot analysis
confirmed the elevated expression of PBK in different GIC
cultures compared to two different normal NSC cultures
(Fig. 1k). The survival times of GBM patients (TCGA)
with the highest and lowest expression of PBK were
compared using Kaplan-Meier estimator. This analysis
showed that the increased expression of PBK correlated
negatively with the survival of mesenchymal subtype
patients (Fig. 1l). The survival results for other subtypes
were not significant.
Taken together, these results indicate that PBK is
strongly upregulated both in primary GIC cultures and
in GBM tissue samples. These observations are con-
sistent with several studies that have demonstrated an
increased expression of PBK in various malignancies
[17, 19, 21, 24, 29–32]. These results prompted us to
further explore the role of PBK in GBM growth and
survival using two approaches to inhibit its function:
knockdown by shRNA and pharmacological blockade
of interaction with targets.
Knockdown of PBK with shRNA reduces viability and
sphere formation, and can increase apoptosis
We created a knockdown of PBK in GICs by using RNAi
technology (Thermo Scientific, Open Biosystems). We
used three different shRNA constructs directed against
PBK mRNA and a non-silencing shRNA as a control.
These shRNA constructs were used to knock down PBK
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in GIC cultures (T59, T65 and T08). The knockdown
efficiency was monitored by qPCR (Additional file 2:
Figure S1 and Additional file 3: Table S2) and Western
blot analysis, which showed that shRNAs led to efficient
protein knockdowns in several cultures (Fig. 2a). The
strongest PBK protein knockdowns were obtained with
shRNA1 in T59 and shRNA3 in T65 and T08 (Fig. 2a).
In GIC culture T59 treated with shRNA3 we could not
detect PBK knockdown at mRNA level (Additional file
2: Figure S1). However, we detected slightly increased
levels of PBK protein (Fig. 2a). To investigate the degree
of linear dependence between the knockdown efficien-
cies at the transcript and protein levels we compared
the qPCR data to the quantified western data using
Pearson product–moment correlation coefficient (PPMCC
r) calculation. Correlation was good (r = 0.68), very good
(r = 0.77) and excellent (r = 0.97) for T59, T08 and T65
respectively.
Immunostaining of cryosections from T08 tumorspheres
treated with shRNA2 and shRNA3 further confirmed the
decrease of PBK expression compared to non-silencing
shRNA controls. PBK immunostaining was strongly re-
duced by shRNA2 and completely abolished by shRNA3
(Fig. 2b left to right), essentially mirroring the results
obtained with Western blotting.
The above results indicate that an efficient knockdown
of PBK at the protein level can be obtained using shRNA
vectors. Therefore, to elucidate the role of PBK in cellu-
lar functions involved in the growth and survival of GIC
cultures, we performed viability, sphere formation and
apoptosis assays on the three GIC cultures (T59, T65
and T08) featuring PBK knock-down.
Viability, number of spheres formed, and sphere size
were all reduced, in most cases at statistically signifi-
cant levels, in GIC cultures with all three shRNA con-
structs as compared to non-silencing shRNA controls
(Fig. 2c-e). To calculate the degree of linear dependence
between the knockdown efficiencies and the results of the
functional assays we used PPMCC. Correlation between
the results of the cell viability assay and knockdown
efficiency was very good (r = 0.82) for T59 and excel-
lent for T65 and T08 (r = 0.91 and r = 0.93 respect-
ively). Correlation between the number of spheres and
the knockdown efficiency was excellent for all three cul-
tures (r = 0.9, r = 0.93 and r = 0.97 in T59, T65 and T08
respectively). Also the size of the spheres correlated
nicely to the knockdown efficiency values and ranged
from r = 0.76 in T65 to r = 0.84 in T59 and r = 0.99 in
T08. Because the decrease in viability was paralleled by
decreases in sphere formation and size, it is likely to be
due in large part to inhibition of cell proliferation and
growth. Since PBK seems to play an important role in the
mitotic phase of the cell cycle of some cancer cell types,
we also investigated the effect of PBK knockdown on
cells arrested in the G2/M phase of the cell cycle [30].
Only one of the three GIC cultures was arrested with the
three different knockdown constructs in the G2/M phase
of the cell cycle (data not shown).
To assess the effect of PBK knockdown specifically
on cell survival, we quantitated apoptosis by measur-
ing caspase-3 activity. Caspase-3 activity was increased
by about 4-fold in T08 by all three shRNAs relative to
ns-shRNA, whereas it was unaffected or even reduced in
T59 and T65 (Additional file 4: Figure S2). Thus, PBK
knockdown has stronger effects on proliferation and
growth than on cell death in GIC cultures.
Effects of HI-TOPK-032 on viability, sphere formation, and
apoptosis
To examine the effects of HI-TOPK-032 (an agonist that
binds to the active site of PBK [28], cells from each of
the three GIC cultures were treated with 5 μM and
10 μM HI-TOPK-032, concentrations shown previously
to efficiently inhibit PBK in other cancer cell lines [28].
Cells were treated for three days and viability was assessed
for a period of 24 h. Viability was powerfully inhibited
(more than 90 %) in a dose-dependent manner (Fig. 3a).
Sphere formation was assessed in the same cultures after
(See figure on previous page.)
Fig. 1 Expression of PBK in different GIC cultures. a Expression of PBK gene in NFCs and seven different GIC cultures. Box plot shows significantly
increased expression levels of PBK in GIC cultures. Relative expression of PBK was calculated using normal NSCs from the adult human brain as
a reference (Relative expression of PBK in NSCs = 1, not shown). Relative expression of PBK was not significantly increased in NFCs (p = 0.057).
b Expression of PBK gene in GBM tissue samples from TCGA. PBK was significantly up-regulated in proneural and down-regulated in mesenchymal
subtypes of GBM. PBK expression in different subtypes was performed using the classical subtype as a reference. Common for A and B: The bottom
and top of each box in box and whisker plots indicate the 25th and 75th percentile (the lower and upper quartiles, respectively), and the band near
the middle of the box represents the 50th percentile (the median) (c-h) Immunostaining of cryosections of GIC spheres (T65 and T08) shows
expression of PBK (red) and its cellular co-localization with Hoechst (blue). Scale bar = 20 μm. i, j Immunolabeling of a GBM tissue with PBK
antibody shows its extensive presence in the GBM tissue compared to the normal cortex brain tissue. Scale bar = 20 μm. k Western blot
analysis done on seven GIC cultures shows a clear upregulation of PBK as compared to that in the two normal NSC cultures. ACTB was used as a
control. l Kaplan-Meier graph showing patient survival in mesenchymal subtype of GBM (TCGA). The survival times of GBM patients with highest
(30 %) and lowest (30 %) expression of PBK were compared (p = 0.0046 according to Gehan-Breslow-Wilcoxon test). Increased expression of PBK
correlated negatively with patient survival. Asterisks correspond to p values and indicate level of significance: * = (p ≈ 0.01-0.05), ** = (p ≈ 0.001-0.01)
and **** = (p < 0.0001)
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10 days of culture. Both sphere number and sphere area
were also massively reduced (by 80-90 % in all cases;
Fig. 3b, c). This was paralleled by a substantial, dose-
dependent increase in apoptosis (Fig. 3d). Thus, the
massive decrease in viability is clearly due in large part to
decreases in proliferation and in cell survival.
Fig. 2 PBK knockdown with lentiviral shRNAs led to reduction in viability and sphere forming capacity in GICs. a Western blot analyses demonstrated
down-regulation of PBK protein level in T65, T08 and T59 shRNAs 1, 2 and 3 cell lines compared to non-silencing cells and the original tumor. ACTB
was used as a control. b Immunofluorescence analysis of cryosections of GIC spheres transduced with shRNA 2 and 3 compared to the
control, shows the loss of PBK protein in the cells present in the spheres. This loss of PBK directly correlated to the loss of GFP. Scale bar =
20 μm. c Quantitative analyses of PBK knockdown cell lines of different GICs showed a significant decrease (n = 5 in each assessment) in viability
of knockdown cells compared to the non-silencing controls. d, e Analysis of sphere formation capacity - Sphere numbers and sphere areas of the
PBK knockdown cell lines were also diminished as compared to the non-silencing controls. PBK knockdown led to an efficient decrease in the
sphere formation capacity of GICs. Error bars = SD; n = 5. Asterisks correspond to p values and indicate level of significance: * = (p ≈ 0.01-0.05),
** = (p ≈ 0.001-0.01) and **** = (p < 0.0001)
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We also tested the effect of HI-TOPK-032 (5 μM) on
one of the knockdown cell lines (shRNA3) and its non-
silencing control for each of the cultures T65, T08, and
T59, and found that cells featuring PBK knockdown
were more resistant than non-silencing control cells to
HI-TOPK-032 treatment with respect to cell viability,
sphere forming capacity and apoptosis (Additional file 5:
Figure S3). These findings indicate that the effect of HI-
TOPK-032 is stronger and has a more specific effect in
cells containing more PBK protein.
We have also performed an in vitro dilution assay
using single cell sorting of T08 control and HI-TOPK-
032 treated (5 μM) cells. The effect of HI-TOPK-032
on the clonally derived spheres was similar to that
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seen in the experiments described above (Additional
file 6: Figure S7).
Microarray analysis
Differentially regulated genes were identified using the
Rank product analysis and 1 % false discovery rate
(FDR). For the analysis of PBK knockdowns; we included
shRNA2 and shRNA3 of T08 tumor culture with their
corresponding non-silencing controls (all in triplicate).
We identified 1585 differentially regulated genes, 963
and 622 being up- and down-regulated, respectively. For
the transcriptome analysis of PBK inhibitor–treated sam-
ples; T65, T08 and T59 tumor cultures were treated with
PBK inhibitor at a concentration of 5 μm (all in tripli-
cate). We identified 2712 differentially expressed genes,
1380 up- and 1332 down-regulated genes compared to
the control. Directly comparing the gene lists; we found
that 549 genes were overlapping between the PBK-
knockdown and the inhibitor-treated groups. These genes
were mostly involved in developmental processes and
adhesion (Gene Ontology analysis; Additional file 7: Table
S3). Pathway analysis was conducted individually for both
groups, and interestingly we identified a similar profile of
pathways being significantly regulated in both knock-
downs and inhibitor-treated cells: metabolic pathways,
cell cycle, focal adhesion, pathways in cancer, cell adhe-
sion molecules and ECM-receptor interaction.
In addition to this, we have also analyzed a few cancer-
related pathways such as Wnt, Notch and EGF in indi-
vidual KD and inhibitor treated cultures. We found that
several important genes in these pathways were differen-
tially regulated in different cultures compared to their
respective controls. Principal component analysis showed
a significant differential distribution of Wnt, Notch, and
EGF-related genes in shRNA/PBK inhibitor treated cell
lines compared to controls (data not shown).
ERK and p38 MAPK signaling
We next investigated the effect of HI-TOPK-032 on the
ERK signaling pathway, which is a direct downstream
target of PBK. Cells from two of the GIC cultures were
treated with HI-TOPK-032 for three days and then cell
lysates were examined by Western blot analysis. Inhib-
ition of PBK by HI-TOPK-032 led to moderate decre-
ment in total ERK1/2 levels and significant reduction in
phosphorylated ERK1/2 (Fig. 3e).
PBK is necessary for appropriate activation and func-
tion of the p38 MAP Kinase pathway by growth fac-
tors [18, 23]. The regulation of p38 phosphorylation
status by PBK is mediated via several factors including
ERK1/2 [17, 21]. Western blot showed down-regulation
of phospho-p38 MAP Kinase (Thr180/Tyr182) in cultures
treated with HI-TOPK-032 (Fig. 3f). We also investigated
the influence of PBK knockdown on levels of phospho-
p38 MAP Kinase. In GIC cultures featuring PBK knock-
down the levels of phospho-p38 MAP Kinase (Thr180/
Tyr182) were also decreased (Additional file 8: Figure S8).
Taken together, these results suggest that PBK plays a
vital role in the growth and survival of GIC cultures and
that HI-TOPK-032 is an efficient antagonist of PBK.
Therapeutic inhibition of PBK attenuates growth of
subcutaneous tumor xenografts in vivo
To further investigate the effectiveness of PBK inhibition
we performed an experimental therapy approach using
exogenously delivered PBK inhibitor to severe combined
immune-deficient (SCID) mice with subcutaneous tumors.
To establish these tumors we injected T08 cells subcuta-
neously into the flank, and then injected the inhibitor
locally into the resultant tumor starting three weeks later.
Mice were injected with vehicle control or HI-TOPK-032
at 5 or 10 mg/ kg three times a week over a period of
28 days. This treatment regimen significantly inhibited
tumor growth (mean tumor volume) by more than 3–5
fold relative to controls in a dose-dependent manner
(Fig. 4a, b). Mice appeared to tolerate the intra-tumor
injection of HI-TOPK-032 without any signs of toxicity or
loss of body weight (Fig. 4c). Thus, HI-TOPK-032 appears
to arrest tumor growth through inhibition of PBK in vivo.
Immunohistochemical analysis of the proliferation
marker Ki67 (Fig. 4d) and the apoptosis marker cleaved
caspase-3 (Fig. 4e) showed a reduction in the proportion
of Ki67-positive cells and a slight increase in apoptosis
in HI-TOPK-032-treated tumors compared with controls.
These findings support the interpretation that the ob-
served decline of tumor growth in the inhibitor-treated
tumors in vivo is caused by a reduction of proliferation
and an increase in apoptosis.
Effects on wide range of GBM patient samples: in vitro
simulation of treatment with inhibitor
As a clear effect of PBK blockade had now been estab-
lished by various means and as the in vivo use of HI-
TOPK-032 seemed to imply a potential treatment for
tumor reduction, we decided to investigate the relative
effects on tumor cells compared with NSCs from the brain
and their differentiated counterparts. Tumor-derived stem
cells from 22 GBM patients were cultured from primary
tumor tissue samples. These were cultured in VML
(serum free) media and Failsafe media (1 % serum +mito-
gens). 18 cultures thrived in VML conditions while all 22
thrived in Failsafe. Once cultures were established they
were incubated for three days in media containing HI-
TOPK-032 inhibitor at 0, 1.75, 3.5 and 5 μM concen-
trations. Cells were plated at 50,000 cells per well. After
three days cells were then harvested and total cell number,
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Fig. 4 Anti-tumor effects in tumor xenografts upon inhibition of PBK through administration of HI-TOPK-032. a T08 tumor cells were subcutaneously
transplanted in the right flank of SCID mice. After establishment of tumors, mice were treated three times weekly by intra-tumoral injection of
(i) control and (ii) HI-TOPK-032 (5 and 10 mg/kg) suspensions. The tumors were extracted after 4 weeks of treatment and a representative tumor
from each group is shown. b Mean tumor volume was calculated. Error bars = SD. Mean tumor volumes of HI-TOPK-032 treated tumors (5 and
10 mg/kg) were significantly different than the control group (p < 0.05 and p < 0.005 respectively). c HI-TOPK-032 had no effect on mouse body
weight. Mice in both treated and untreated groups were weighed once a week. Error bars = SD (d, e). Immunofluorescence analysis of HI-TOPK-032
(10 mg/kg) treated and control tumor cryosections stained for Ki-67 and cleaved caspase-3 expression. Scale bar = 20 μm
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number of dead cells and net number of live cells
were determined (Fig. 5 and Additional file 9: Figure
S4). Six cultures of normal NSCs were grown and
tested from three human biopsies as described for the
tumor-derived cultures. Cells differentiated from stem
cell cultures were also tested (n = 3) for both tumor
and normal patients.
Total cell numbers were maintained in all culture types
except for GICs grown adherently in Failsafe, which de-
creased in number in 5 μM of inhibitor compared to no
inhibitor (P = 0.019, 2 tailed T-test). However, the num-
ber of dead cells increased in all cultures with increasing
concentration of inhibitor (P < 0.05) (Additional file 9:
Figure S4).
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differentiated GIC cultures (e) but not in differentiated NSC cultures (b) thus presenting a narrow therapeutic window (indicated with red rectangle)
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Therefore, results for net live cells were analyzed in
more detail. Using two-way Anova, we assessed the
interaction between concentration of inhibitor and cell
type. Interaction with cell type was not statistically sig-
nificant whereas concentration of inhibitor reduced net
cell numbers significantly in a dose-dependent manner
(P = 0.0031). We then tested whether normal stem cells
fared better than GICs. At an inhibitor concentration of
3.5 μM both groups of tumor stem cells experienced a
significant reduction in net live cells (P</=0.05) but
reduction in normal stem cells did not reach significance
(P = 0.17). At an inhibitor concentration of 3.5 μM
differentiated cells of both normal and tumor origin ex-
hibited no significant reduction in net live cell numbers
(P = 0.69 and 0.67 respectively). Thus there was a slight
differential tolerance to the inhibitor treatment in nor-
mal NSCs and in differentiated cells from both tumor
and normal tissue sources.
Discussion
GBM, the most prevalent and malignant primary brain
tumor, is highly resistant to conventional therapies
[33–35]. Tumor recurrence is the major issue in the
treatment of this tumor, and has been attributed to the
stem cell population in GBM [6, 36]. Through the estab-
lishment of neurospheres, GBM cells can be enriched
for GICs [37], and this GIC-enriched population pro-
vides a good opportunity to identify novel therapeutic
targets in malignant GBM. Several previous reports have
linked increased expression of PBK to various cancers
including lymphoma, leukemia, melanoma, colorectal
cancer, breast cancer, lung cancer and cholangiocarci-
noma [21, 24, 28, 29, 31, 38], but PBK expression has not
been reported in GBM.
We recently compared PBK gene expression in GICs
to that in NSCs (12) and subsequently found that PBK
expression was upregulated in GICs from all patients
investigated (Stangeland et al., submitted). This was
confirmed at the protein level and it was further shown
that the protein expression of PBK in GBM tissues was
high relative to normal cortical tissues (Stangeland et al.,
submitted).
The strong and consistent upregulation of PBK in
GICs prompted us to test whether PBK is involved in
the maintenance of key tumorigenic properties. To do
this, we used RNAi technology and pharmacological
inhibition of PBK in three GIC cultures that had particu-
larly high levels of PBK protein. Both treatments led to
substantial decrements in viability and sphere formation
in GIC cultures, and pharmacological inhibition also
caused a substantial increase in apoptosis. Thus, PBK
emerges as a particularly interesting potential thera-
peutic target for arresting the growth of GBM.
RNAi technology has been widely used in mammalian
cells to suppress the expression of a variety of genes and
thereby facilitates the definition of the functional roles
of genes, especially in diseases. We have delivered three
shRNAs specific for PBK using a lentiviral system. The
different shRNA constructs were able to efficiently knock
down PBK gene expression. We found that PBK knock-
down significantly decreased viability and sphere forming
ability in GIC cultures.
To further validate PBK’s role in GIC growth and
survival, we treated different GIC cultures with a pharma-
cological inhibitor used previously to target PBK in colon
cancer cells [28]. Different GICs treated with two different
concentrations of this inhibitor show a marked, dose-
dependent reduction in viability and sphere formation. Of
particular note is the huge increase in apoptosis obtained
using this method, which was not observed with shRNA
treatment. This probably reflects the different modes of
action of shRNAs and pharmacological inhibition, the
latter having the more direct effect on the protein target.
Analysis of the downstream targets ERK1/2 and p38 MAP
kinase showed a marked reduction of phosphorylated
forms of these proteins in both HI-TOPK-032 treated cells
and knockdown cultures. Decrement in phospho ERK1/2
and phospho p38 levels correlated well with the reduction
in cell viability in HI-TOPK-032 treated cells (Fig. 3a, e-f).
These results are in agreement with studies in other
cancers [17] and further emphasize the role of PBK signal-
ling in tumor cell proliferation.
Our findings are similar to those of Kim and co-workers
[28], who showed that the administration of HI-TOPK-
032 at a dose of 1 and 10 mg/kg bodyweight as an experi-
mental therapy for pre-established subcutaneous colon
cancer xenografts led to a massive reduction in tumor vol-
ume. We find that HI-TOPK-032 at doses of 5 and 10 mg/
kg markedly attenuates the growth of pre-established sub-
cutaneous GBM xenografts. Notably, our immunohistolo-
gical investigation of the HI-TOPK-032-treated tumors
revealed a decrease in proliferating cells accompanied by a
slight increase in the number of apoptotic cells.
Having established a significant role for PBK in three
gliomas we set out to test whether inhibition of PBK
would affect a large number of tumors and to gauge
how well normal cells fare under a treatment scenario.
Twenty-two out of 22 primary tumor cell lines were
severely reduced in net live cell numbers after three days
of treatment, and cell death was pronounced in all sam-
ples. Normal NSCs seemed to withstand the treatment
better at 3.5 μM than GICs. Both normal- and tumor-
derived differentiated cells fared better than GICs. In
summary, our results support an effect of the inhibitor
when given directly into the tumor. The possibility of sys-
temic administration should be investigated when new
inhibitors have been developed.
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Conclusions
Our observations in vitro and in vivo confirm the func-
tional importance of PBK in the growth and survival of
GBM cells. PBK may therefore serve as a potential thera-
peutic target in GBM tumors.
Methods
Cell culture
Tumor biopsies were obtained from consenting patients
as approved by the Norwegian National Committee for
Medical Research Ethics. Briefly, primary GBM tissue
samples were washed, and enzymatically dissociated to
single cells by incubation in Trypsin-EDTA (Invitrogen).
Trypsin treatment was blocked by adding 2 mg/ml
human albumin (Octapharma Pharmazeutika Produk-
tiones, Austria) and the cells were then washed in
Leibowitz-15 medium (L-15, Invitrogen). The cells were
resuspended as single cells and cultured in a chemically
defined serum-free neurosphere medium consisting of
10 ng/ml basic fibroblast growth factor (bFGF) and
20 ng/ml epidermal growth factor (EGF) (both R&D
Inc., Minneapolis, MN), B27-supplement (1:50, Invitrogen),
100 U/ml Penicillin/streptomycin (Lonza, Switzerland),
1 ng/ml Heparin (Leo Pharma, Denmark) and 8 mM
Hepes (Lonza) in Dulbecco’s modified essential medium
with nutrient mix F-12 and Glutamax (DMEM/F12,
Invitrogen) (‘VML’ medium). Cells were cultured at a
density of 105 cells/ml in 75 cm2 non-treated cell cul-
turing flasks. GIC cultures were characterized for the
following stemness markers- CD133, CD44, SSEA-1/
CD15, CXCR4, CD9, CD166, A2B5 (Additional file 10:
Figure S5). GIC cultures were routinely characterized
for their tumor forming capability by transplanting
them into the brain of SCID mice (Additional file 11:
Figure S6).
Adherent NSCs were grown in modified neurosphere
medium containing 1 % FBS, 10 ng/ml bFGF and 20 ng/
ml TGF α (‘Failsafe medium’) [39]. NSCs were isolated
from SVZ and hippocampus.
Cells of the ReNcell VM Human Neural Progenitor
Cell Line (Millipore, SCC008) were grown as spheres in
serum free Neurobasal A medium (Life technologies,
10888–022) containing B27 (Gibco-BRL, Rockville, MD,
USA), 10 ng/ml basic fibroblast growth factor, and
20 ng/ml epidermal growth factor (both from R&D Sys-
tems, Minneapolis, MN, USA).
In vitro differentiation
Dissociated cells (tumor-derived and normal NSCs)
were plated at 50 000 cells/well in 6 well plates (Nunc,
VWR Norge) coated with 15 μg/ml poly-L-ornithine
(Sigma, St. Louis, MO). DMEM/F12 medium was aug-
mented with fetal calf serum (3.75 %; PAA Laborator-
ies, Pasching, Austria) and 25 μl/ml B-27 with vitamin
A (Invitrogen), 1 μg/ml laminin and 10 μl/ml of Pen/
Strep. All cultures were kept in an incubator at 5–6 %
CO2, pH 7.2-7.4 [40].
RNA isolation and real-time quantitative
reverse-transcription PCR (qPCR)
Total RNA from cells (2×106) was isolated using the
RNeasy Mini Kit (Qiagen). The concentration of each
RNA sample was determined by using the Nanodrop
spectrophotometer. cDNA was synthesized from 1 μg
of RNA using a QuantiTect Reverse Transcription kit
(Qiagen). qPCR was performed on a ABI PRISM 7900HT
(Applied Biosystems) with SYBR® Premix Ex Taq™ (Perfect
Real Time) (Takara) according to the manufacturer's
instructions. Experiments were performed on at least
three biological replicates (different passages). Crossing
point (CP) values were generated using second-derivative
calculation software (SDS2.2). Expression levels were cal-
culated using REST software [41]. The primers for qPCR
were designed according to Vector NTI-based Web
service for primer design: Probe Wiz Server, Center for
Biological Sequence Analysis [42]. The oligonucleotide
sequences used for PBK expression analyses were:
Oli_7_DIR_PBK_set1_1515_TGGATCTACTGACATT
AGCACTTTGTA, Oli_8_REV_PBK_set1_1844_CCAAA
GTGTCCTTTATTCTTTATCATC, Oli_9_DIR_PBK_set2_
904_TTACTTTGTGGGAAATGATGACTTTAT, Oli_10_
REV_PBK_set2_1107_CATTAGTGCATACAGAGAAG
AGTTCAA.
Western blot
The cells (2-6 × 106) were trypsinized, washed with PBS
and homogenized by triturating in Cell Extraction (CE)
Buffer (Mammalian cell extraction kit K269-500, Biovi-
sion). The homogenates were then vortexed for a few
seconds, incubated on ice for 10 min and finally centri-
fuged at max speed (microfuge) for 1 min through a
QIAshredder (Qiagen). The supernatants were collected,
and the amount of total protein was determined using
the BCA protein assay kit (Thermo Scientific). 20–40 μg
of whole protein extracts were mixed with the loading
buffer (NuPAGE) and loaded onto a 4-12 % gradient
Nu-PAGE gel (Invitrogen). Protein gels were blotted
onto a 0.45 μm PVDF membrane. The membrane was
blocked with 5 % skimmed milk in TBS/0.1 % Tween 20
(TBST) and probed with primary antibodies in TBST
and 5 % skimmed milk. Secondary antibodies were HRP-
conjugated anti-rabbit IgG, anti-mouse IgG and anti-
goat IgG (1/10 000 in 5 % skimmed milk in TBST).
The blots were developed using Lumiglo Reserve CL
Substrate kit, detected by Kodak Molecular Imaging Sys-
tem (Kodak MI, version 5.0) or the Epi Chemi II Dark-
room (UVP-Laboratory Products) and Labworks software
(UVP). Western blot was performed using rabbit anti-
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PBK [#4942 (Cell Signaling), 1:1000], Phospho ERK 1 and
2 [#9101 (Cell Signaling), 1:1000], Total ERK 1 and 2
[#9102 (Cell Signaling), 1:1000], Phospho-p38 MAP Kin-
ase (Thr180/Tyr182) [#9216 (Cell Signaling) (mouse)
1:1000] and ACTIN [#4967 (Cell Signaling), 1:1000] anti-
bodies. For secondary antibody we used ECL Anti-rabbit
IgG-HRP [NA934 (Amersham), 1:10000]. To calculate
relative protein expression (RPE) the intensities of the
protein bands from Western blots were quantified using
Adobe Photoshop and normalized to the intensities of the
corresponding β-actin (ACTB) bands. The RPE values
were used for calculation of the Pearson product–moment
correlation coefficient r.
Flow cytometry
Flow cytometry analysis of surface markers was per-
formed as previously described [43]. Intracellular stain-
ing was performed by using Fixation/Permeabilization
Solution Kit (BD Pharmingen), where cells were incu-
bated with primary antibody over night, followed by
washing and then incubated with secondary antibody for
2 h. Cells stained with secondary antibodies alone were
used as control for gating. The following antibodies were
used: CD166-PE, CD9- FITC, CXCR4-PE, m/hCD44-APC
(eBioscience, San Deigo, CA), CD133/2-PE and anti-m/
hAPC-A2B5 (Miltenyi, Billerica, MA).
Immunolabeling and confocal microscopy
Tumor spheres were spun down, fixed in 4 % parafor-
maldehyde, cryo-protected in 20 % sucrose in PBS,
cryo-embedded in OCT (Tissue-TEK, Sakura Finetek,
CA) and immunostained as described in [44, 45]. GBM
tissue samples, cortex from the normal brain, and HI-
TOPK-032 treated tissue from the subcutaneous tumors
were fixed, cryo-protected and cryo-embedded in a similar
way. Sections of 12 μm were made with a cryostat,
mounted on Super Frost (Thermo scientific) microscope
slides and were immunostained [44].
Immunostaining was done using the following primary
antibodies: anti-PBK [#612170 (BD Transduction Labora-
tories), Mouse, 1:100], anti-Ki67 [#SC15402 (Santa Cruz),
Rabbit, 1:200] and anti-Cleaved Caspase-3 [#9661 (Cell
Signaling), Rabbit, 1:400]. Secondary antibodies used were
goat anti-Mouse and goat anti-Rabbit Cy3 conjugates
(Amersham Pharmacia Biosciences). Cells and sections
were fluorescence counterstained with Hoechst 33342 and
mounted in 50:50 PBS: glycerol. Negative and positive
controls were included in each experiment. Confocal
images were acquired with a Zeiss Meta 510 confocal laser
scanning microscope.
Lentiviral mediated shRNA knockdown
Three different GIC cultures were used to establish PBK
knockdown cell lines each with three different shRNA
constructs (RMM4431-98972202, RHS4430-101071930,
RHS4430-101072940, Thermo Scientific, Open Biosys-
tems). Nine μg of plasmid DNA were transfected into
the 293FT cell line using Arrest-In transfection reagent
(according to the manufacturer’s protocol). Briefly, viral
supernatants collected after 48 and 72 h were centrifuged
at 3000 rpm for 20 min at 4 °C and filtered through a
sterile 0.45 μm low protein binding filter (Sarstedt). The
virus was then concentrated in sterile SW28 ultracen-
trifuge tubes by ultracentrifugation (Beckman Optima™
LE-80 K ultracentrifuge) equipped with a SW-28 rotor at
23,000 rpm for 1.5 h at 4 °C. The pellet was resuspended
in 200 μl of DMEM and aliquots of the concentrated
virus were stored at −80 °C. Tumor cells (105 cells/well)
were then transduced in 24 well plates by adding 10 μl
concentrated virus/well and the cells were incubated for
48 h at 37 °C in 5 % CO2. Three to five days after trans-
duction, GFP positive cells were purified by FACS sorting
using a FACS Diva cell sorter equipped with an argon ion
laser, ‘TurboSort Plus’ option, and Diva software (Becton
Dickinson). The cells were then selected in 2 μg/ml Puro-
mycin (Sigma, USA) for 3–4 weeks and used for func-
tional assays.
PBK/TOPK inhibitor
The PBK/TOPK inhibitor HI-TOPK-032 was purchased
from Inter BioScreen, Russia. For the functional assays
done on HI-TOPK-032 treated cells, cells were first
incubated with the inhibitor at a concentration of 5 μM
and 10 μM for 3 days. This HI-TOPK-032 is expected to
bind to the active site of PBK [28]. Stock concentration
(1 mM) of HI-TOPK-032 was dissolved in 1 ml of
DMSO.
Cell viability assay
A colorimetric test based on tetrazolium salt-XTT con-
version (Roche Diagnostics, Indianapolis, IN) was used
to measure the viability in control, PBK knockdown cell
lines and HI-TOPK-032 treated cells, according to the
manufacturer’s instructions. Commonly referred to as
a cell viability assay, this actually reflects all aspects of
cell activity including cell growth, cell proliferation,
and any changes in metabolic state in the absence of
growth and proliferation. Briefly, cells were plated at a
density of 1 × 104 cells per well of a 96-well plate. We
measured five wells for each cell sample. The colorimet-
ric changes (absorbance) were measured after 24 h at
490 nm using a plate reader (Victor™ X5, Perkin Elmer
2030 Multi-label reader) after the addition of XTT
reagent (50 μl/well).
Sphere-forming assay
Spheres (control, PBK knockdown cell lines and HI-
TOPK-032 treated cells) were dissociated into single cell
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suspensions and 500 cells per well were plated in ultra-
low attachment 96-well plates (Sarstedt, USA). The num-
ber and diameter of spheres in 10 wells were measured
for each cell sample. The formation of spheres per well
was evaluated 10 days after commencement of culturing
them. Only the spheres above 50 μm were taken into
consideration. The number and the size of spheres (aver-
age area) were measured by using GelCount™ (Oxford
Optronix, UK).
Apoptosis
The Homogeneous Caspases Assay, which is a fluorimet-
ric test used for the quantitation of caspase activity in
vitro (Roche Diagnostics GmbH, Germany) was used to
determine the rate of apoptosis in control and PBK
knockdown cell lines, and HI-TOPK-032 treated cells,
according to the manufacturer’s instructions. Briefly,
control and PBK knockdown cell lines were plated at a
density of 5 × 103 cells per well of a 96-well plate. Three
wells were measured for each cell sample. The fluorimet-
ric changes were measured after 24 h at 485/535 nm
using a plate reader (Victor™ X5, Perkin Elmer 2030, Mul-
tilabel reader) after the addition of substrate (100 μl/well).
Microarray hybridization and analysis of microarray data
RNA was amplified and hybridized to Illumina Human
HT-12 v4 microarrays. Analysis and statistics were
done using J-Express (Molmine) and Web Gestalt [46].
Microarrays were quantile normalized and differential
gene analysis carried out using Rank product analysis
[47]. Pathways and gene ontology were obtained from
KEGG [48], Wiki pathways [49] and Gene Ontology
[50]. Microarray data from our lab are MIAME com-
pliant and the following link has been created to allow
review of the data in Gene Expression Omnibus [51]
(GEO accession number is GSE53800): https://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE53800.
Xenograft mouse model for testing of HI-TOPK-032
All animal procedures were approved by the National
Animal Research Authority (NARA #4799). C.B.-17 se-
verely combined immunodeficient (SCID) male mice (8–9
weeks old) were obtained from Taconic (Ejby, Denmark).
They were maintained in a minimal disease unit under
“specific pathogen-free” conditions according to the
guidelines by the NARA and acclimatized for >1 week.
Prior to the inoculation of cells, mice were anesthetized
with a subcutaneous injection of Hypnorm (10 mg/mL
fluanisone and 0.315 mg/mL fentanyl citrate; Veta Pharma)
and Dormicum (5 mg/mL midazolam; Roche). Mice
were divided into three groups: (i) control group (n = 4),
(ii) HI-TOPK-032 5 mg/kg of bodyweight (n = 4) and
(iii) HI-TOPK-032 10 mg/kg of bodyweight (n = 4).
GICs from T08 expressing GFP were suspended in
neurosphere medium and 1:4 Matrigel (Basement mem-
brane matrix, BD Biosciences) and 1.5 × 106 cells/100 μl
were inoculated subcutaneously into the right flank of
each mouse. When tumors started to become visible the
mice were given treatment three times weekly for 28 days
with intra-tumoral injections according to their assigned
groups. Stock concentration (100 mM) of HI-TOPK-032
in DMSO was diluted in physiological NaCl (9 mg/ml;
Braun) and the control group received an equivalent
amount of NaCl solution. All animals were monitored
for adverse effects especially due to inhibitor administra-
tion and examined regularly for general appearance,
signs of distress (local and systemic toxicity), and with
weight measurements.
All mice were sacrificed when tumors became > 1.5 cm
in diameter. Tumors were extracted and measurements
obtained for 3 planes. Tumor volumes were calculated
using the formula for a triaxial ellipsoid (4/3xr1xr2xr3xπ).
Xenograft tumors were fixed overnight in 10 % buffered
formalin, cryoprotected in 20 % sucrose for 24 h and then
cryo-embedded in OCT (Tissue-TEK, Sakura Finetek,
CA) and stored at −20 °C. Tumors were cut into 12 μm
sections for immunolabeling as described previously.
Effects on wide range of GBM patient samples: In vitro
simulation of treatment with inhibitor
Cells were seeded at 50,000 cells per well and HI-TOPK-
032 inhibitor included in the culture media at 0, 1.75,
3.5 and 5 μM in DMSO vehicle (15 μL). Total and dead
cells were counted after three days using a Nucleocoun-
ter (Chemotetec). Total and net live cells were expressed
as fold of the cell numbers for vehicle only. Dead cells
were expressed as % of total cell numbers.
Statistical tests
Statistical evaluation of the results obtained in the func-
tional assays (proliferation, sphere forming ability, apop-
tosis) was done using the non-parametric Mann–Whitney
U-test for two unpaired groups. For the in vitro inhibition
tests Two Way Anova was applied for interaction of
Inhibitor Concentration and Cell Type. For comparison of
individual means for concentration effects, a two tailed
Student’s T-test was applied.
Additional files
Additional file 1: Table S1. This table shows P values and fold change
expression of PBK by qPCR in different GICs patient samples relative to
NSCs control cells.
Additional file 2: Figure S1. Confirmation of PBK knockdown by qPCR.
PBK mRNA was quantified in three GIC lines treated with shRNAs 1, 2 and
3 compared to the Non-silencing controls. Relative expression of PBK
confirmed efficient knockdowns in the following cultures: T65 treated
with shRNAs 2 and 3, T08 treated with all three shRNAs and T59 treated
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with shRNAs 1 and 2. Additional statistical parameters are shown in
Additional file 3: Table S2.
Additional file 3: Table S2. The statistical values to show the relative
expression of PBK in shRNA lines (as shown in Additional file 2: Figure S1)
are presented in this table.
Additional file 4: Figure S2. Induction of cell death by PBK knockdown.
Apoptosis measured as increase in Caspase-3 activity is evident in all KD
lines from T08 GIC cultures but in none of the KD lines from T65 and T59
GIC cultures. Error bars = SD, n = 3. The statistical analysis was performed
using unpaired T-test with Welch’s correction. The asterisks indicate the
level of significance (* ≈ p ≈ 0.01-0.05). The values obtained for knockdown
cultures were compared to the values obtained for NS controls.
Additional file 5: Figure S3. Pharmacological treatment of KD lines
with HI-TOPK-032 reduces viability and sphere forming capacity. One KD
line (shRNA 3) from each of T65, T08 and T59 cell lines together with the
respective Non-silencing control cells exhibited reduced viability (A) and
sphere formation (B), sphere size (C) and increased apoptosis (D) when
treated with HI-TOPK-032 (5 μm). All values shown are normalized to the
measurements made in the respective Non-silencing control cultures.
Error bars = SD, n = 3. The statistical analysis was performed using un-
paired T-test with Welch’s correction. The asterisks indicate the level of
significance (* ≈ p ≈ 0.01-0.05). The values obtained for hybrid treatment
(shRNA + inhibitor) were compared to values obtained for shRNA.
Additional file 6: Figure S7. In vitro dilution assay performed on T08
(untreated and treated with HI-TOPK-032 - 5 μm) shows a similar decrease
in the percentage of clonally derived spheres as seen before. We also
performed this assay on the normal NFCs under similar conditions. NFCs
survived the treatment slightly better than the T08 cells. Error bars = SD,
n = 2 for T08 and n = 3 for NFCs.
Additional file 7: Table S3. Gene expression analysis of PBK
knockdown shRNA cell lines (T08 shRNA2, shRNA3 and T65 shRNA2
shRNA3) and PBK inhibitor treated (T65, T08, T59 – all treated with 5 μM).
Additional file 8: Figure S8. Western blot showing phosphorylation
status of the p38 MAP Kinase (Thr180/Tyr182) in the GIC cultures
featuring PBK knockdown, original GIC cultures and one NSC culture. The
relative expression values were calculated using NS as a control (except
for T65 where the original culture was used as a reference).
Additional file 9: Figure S4. Dead cells expressed as percentage of
total cell numbers for cultures for HI-TOPK-032 at various concentrations.
There was an increase of dose dependent cell death with concentration
in all cultures (p < 0.05; A: n = 22; B: n = 18; C: n = 6; D: n = 3; E: n = 3. Error
bars = SEM).
Additional file 10: Figure S5. Immunophenotypic characterization of
GICs shows expression of surface stem cells markers and proliferation
marker. Most of the cells from the three different patients were highly
positive for CD44, CD166, and CD9 in the GICs. On the other hand,
CXCR4, A2B5, CD133, and SSEA1/CD15 vary among patients. The
proliferation marker Ki67 was expressed in 55 % of the cells in T08 and
53 % in T65. (−*) data not available.
Additional file 11: Figure S6. GIC cultures T08 (A) and T65 (B) were
transduced with lentiviral vectors expressing GFP and transplanted
intracranially to SCID-mice. Representative images showing invasive
tumors formed upon xenotransplantation. Scale bar is 1 mm.
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